一、产品概述
紫铆因 是来自Absin品牌的高品质产品,适用于科研实验领域。
更多产品描述请查看优宁维旗下爱必信官网(https://www.absin.cn/butein/abs817867.html?mk_channel=chemicalbook)
二、产品信息
| 货号 | abs817867 |
| SKU货号 | abs817867-5mg |
| 品牌 | Absin |
| 中文名称 | 紫铆因 |
| 英文名称 | Butein |
| CAS号 | 487-52-5 |
| 纯度 | >98% |
| 分子量 | 272.25 |
| 可溶性 | DMSO : ≥ 35 mg/mL (128.56 mM) |
| 外观 | yellow solid |
| 抗原名称 | EGFR |
商品描述
Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR
In vitro(体外研究)
Butein inhibits the epidermal growth factor (EGF)-stimulated auto-phosphotyrosine level of EGF receptor in HepG2 cells, and also inhibits tyrosine-specific protein kinase activities of EGF receptor and p60c-src with IC50 of 65 μM in vitro. The inhibition is competitive to ATP and non-competitive to the phosphate acceptor, poly (Glu, Ala, Tyr) 6:3:1 for EGF receptor tyrosine kinase. In contrast, Butein non-significantly inhibits the activities of serine- and threonine-specific protein kinases such as PKC or PKA. Butein inhibits Nuclear Factor(NF)-κB and NF-κB-regulated gene expression through direct inhibition of IκBα Kinase β on Cysteine 179 Residue. Butein (10 μM) inhibits over 90% iNOS and COX-2 expression, as well as nitrite and TNF-α production in LPS-stimulated RAW 264.7 cells. Butein (10 μM) inhibits LPS-induced DNA binding activity of NF-κB, which is mediated through inhibition of the degradation of inhibitory factor-κB and phosphorylation of Erk1/2 MAP kinase, as well as increases binding of the osteopontin a vb3 integrin receptor. Butein (20 μM) treatment induces morphologic changes of bladder cancer cells BLS(M) from elongated morphology to rounded epithelial-like cells, accompanied by downregulation of vimentin, and gaining of E-cadherin compared to untreated control cells, indicating the reversal of mesenchymal-like phenotype. Butein (20 μM) suppresses motility and invasion capacity of BLS(M) cells, and reverts EMT-like phenotype induced by TNF-α, through the ERK1/2 and NF-κB signaling pathways. Butein inhibits the constitutive activation of STAT3 in HepG2 cells in a dose-dependent manner, with maximum inhibition occurring at 50 μM, mediated through the inhibition of activation of upstream kinases c-Src and Janus-activated kinase2. Butein (50 μM) also could completely inhibit IL-6-induced STAT3 phosphorylation in SNU-387 cells. Butein downregulates the expression of cyclin D1, Bcl-2, Bcl-xL, survivin, and VEGF, markers of STAT3 activation. Butein (50 μM) significantly enhance the apoptotic effects of doxorubicin from 18% to 55% and of paclitaxel from 15% to 42%. Butein is as a powerful antioxidant against lipid and LDL peroxidation. Butein inhibits iron-induced lipid peroxidation in rat brain homogenate with an IC50 of 3.3 μM. Butein is as potent α-tocopherol in reducing the stable free radical diphenyl-2-picrylhydrazyl (DPPH) with IC0.2 of 9.2 μM. Butein also inhibits the activity of xanthine oxidase with an IC50 of 5.9 μM. Butein scavenges the peroxyl radical derived from 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH) in aqueous phase. Furthermore, Butein inhibits copper-catalyzed oxidation of human low-density lipoprotein (LDL) in a concentration-dependent manner. Butein is a chelator of ferrous and copper ions.
In vivo(体内研究)
Butein at 2 mg/kg induces significant inhibition of hepatocellular tumor growth compared with the corn oil-treated controls. At necropsy on day 22 after initial treatment, there is more than 2-fold decrease in tumor growth in the Butein-treated group (mean relativetumor burden, 3.90) compared with the control group (8.46), associated with reduced constitutive p-STAT3 (9% vs 81% of vehicle group), Bcl-2 levels (26% vs 96% of vehicle group), and increased caspase-3 level (98% vs 21% of vehicle group) in HCC tumor tissues. Butein shows antifibrogenic activity. Butein (25 mg/kg/day) reduces serum AST and ALT activation to 35% and 69%, respectively, of control CCl4-induced rat levels. Butein (25 mg/kg/day) reduces liver hydroxyproline contents and TBAR4 concentration to 54% and 54%, respectively. α1(I) collagen and TIMP-1 expression in Butein-treated rats is 28% and 20.3% compared with the values for the respective CCl4-treated control.
三、背景
| 别名 | 紫铆因;2’,3,4,4’-tetrahydroxy Chalcone |
| CAS号 | 487-52-5 |
四、制备和贮存
| 保存方式 | Store at -20℃ for three years(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
五、产品特点
- 品质保证:经过严格的质量控制,确保产品的高品质和稳定性。
- 高纯度:纯度达到<p>>98%</p>。
六、注意事项
- 本产品仅供科学研究使用,不可用于临床诊断或治疗。
- 请在通风良好的环境下操作,佩戴适当的个人防护装备。
- 如不慎接触皮肤或眼睛,请立即用大量清水冲洗并就医。